Biora Therapeutics, Inc. PROG
Set alert
0.88 +0.88 —
Day range unavailable
52-week range unavailable
- Open
- —
- Prev close
- 0.00
- Mkt cap
- 8.18M
- Vol
- 0
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- —
- High
- —
- Forward P/E
- -2.39
- Beta
- 0.00
- Short ratio
- 0.00
- Inst. own
- 29.78%
- Dividend
- 0.00
- Ex-div date
- Earnings
- May 10, 2022
- 50-d avg
- 1.07
- 200-d avg
- 1.78
- 1y target
- 4.00
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 4.00
Recommendation trend
- 1 month ago 2
- 2 months ago 2
- 3 months ago 5
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.12 | -0.13 – -0.12 | -0.56 | +78.6% | 107.00K | -99.6% | 2 |
| Next quarter | -0.12 | -0.13 – -0.11 | -1.23 | +90.2% | 0 | 0.0% | 2 |
| Current year | -0.42 | -0.49 – -0.36 | -2.57 | +83.7% | 100.00K | -99.6% | 2 |
| Next year | -0.37 | -0.49 – -0.26 | -0.42 | +11.9% | 0 | 0.0% | 2 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 14, 2021 | HC Wainwright & Co. | Initiated | — | Buy |
| Jun 3, 2021 | Raymond James | Downgrade | Outperform | Market Perform |
| Jun 3, 2021 | Baird | Downgrade | Outperform | Neutral |
| May 17, 2021 | Wells Fargo | Maintained | — | Underweight |
| May 14, 2021 | Raymond James | Maintained | — | Outperform |
| Feb 8, 2021 | Wells Fargo | Downgrade | Overweight | Underweight |
| Nov 10, 2020 | Raymond James | Maintained | — | Outperform |
| Oct 23, 2020 | BTIG | Initiated | — | Buy |